thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Quality Assurance questions

Question 16 of 20 Intermediate Practical

How should a company respond to an FDA Form 483?

Short answer

Respond in writing within 15 business days so the FDA reviews it before deciding on a warning letter. For each observation, acknowledge it, explain the investigation and root cause, give the correction and systemic action with dates and evidence, and look beyond the cited example.

Why

A Form 483 lists objectionable conditions an investigator saw during an inspection. The FDA states it is not a final agency determination, and that companies are encouraged to respond in writing with a corrective action plan and implement it quickly. A written response is not legally required, but a 2009 FDA notice says the agency will generally allow 15 business days and will review a response received in that time before deciding whether to issue a warning letter.

A late response will not ordinarily delay a warning letter. A strong response treats each observation as a symptom. It says what was found, how widely the company looked for the same problem, what the root cause is, what was done immediately, what systemic actions follow and when, and how effectiveness will be checked.

Evidence such as revised procedures, training records or data from a retrospective review makes it credible. If the observation cites one unvalidated spreadsheet, the response should cover the search for all such spreadsheets. Arguing with every point or promising actions with no dates weakens trust.

Commitments in the response become things an investigator will check at the next inspection, so promise only what will be done. The response also needs updates as actions complete, since the agency judges progress, not intent.

How to work it through

  1. Read each observation with the subject experts and confirm the facts before the investigators leave if possible.
  2. Scope the problem beyond the cited example across products, sites and systems.
  3. Investigate root cause and implement immediate corrections where risk demands.
  4. Write the response observation by observation with actions, owners, dates and evidence.
  5. Submit within 15 business days of the 483.
  6. Track commitments and send updates as actions close.

An example

An inspection ends on a Friday with three observations, including that audit trails on two HPLC systems were not reviewed. The site counts 15 business days and sets an internal deadline five days earlier. The team checks all 14 chromatography systems and finds 6 without audit trail review.

It writes a procedure for review before result approval, reviews 400 results retrospectively and finds 2 undocumented reintegrations, which are investigated. The response lists these numbers, attaches the procedure and commits to a 90-day effectiveness review, with a follow-up letter when it is done.

Where the answer stops holding

A good response cannot fix a weak inspection outcome alone, since the FDA weighs the whole inspection record. Retrospective reviews can uncover new problems that need their own investigation and possibly reporting. The 15 business day window is FDA policy for warning letter review, not a statutory deadline.

A strong answer covers

  • 15 business days for review before warning letter decisions
  • Observation treated as a symptom with broader scope
  • Root cause, correction and systemic actions with dates
  • Evidence attached
  • Commitments tracked and updated

Common mistakes

  • Fixing only the single example the investigator cited.
  • Promising actions without owners, dates or evidence.
  • Assuming a 483 is a final finding of violation.